352 related articles for article (PubMed ID: 24267154)
1. Targeting pericytes for angiogenic therapies.
Kelly-Goss MR; Sweat RS; Stapor PC; Peirce SM; Murfee WL
Microcirculation; 2014 May; 21(4):345-57. PubMed ID: 24267154
[TBL] [Abstract][Full Text] [Related]
2. Pericyte dynamics during angiogenesis: new insights from new identities.
Stapor PC; Sweat RS; Dashti DC; Betancourt AM; Murfee WL
J Vasc Res; 2014; 51(3):163-74. PubMed ID: 24853910
[TBL] [Abstract][Full Text] [Related]
3. Pericytes: a double-edged sword in cancer therapy.
Meng MB; Zaorsky NG; Deng L; Wang HH; Chao J; Zhao LJ; Yuan ZY; Ping W
Future Oncol; 2015; 11(1):169-79. PubMed ID: 25143028
[TBL] [Abstract][Full Text] [Related]
4. Pericyte-targeting drug delivery and tissue engineering.
Kang E; Shin JW
Int J Nanomedicine; 2016; 11():2397-406. PubMed ID: 27313454
[TBL] [Abstract][Full Text] [Related]
5. Role of pericytes in angiogenesis: focus on cancer angiogenesis and anti-angiogenic therapy.
Chen Z; Xu XH; Hu J
Neoplasma; 2016; 63(2):173-82. PubMed ID: 26774138
[TBL] [Abstract][Full Text] [Related]
6. Targeting olfactomedin-like 3 inhibits tumor growth by impairing angiogenesis and pericyte coverage.
Miljkovic-Licina M; Hammel P; Garrido-Urbani S; Lee BP; Meguenani M; Chaabane C; Bochaton-Piallat ML; Imhof BA
Mol Cancer Ther; 2012 Dec; 11(12):2588-99. PubMed ID: 23002094
[TBL] [Abstract][Full Text] [Related]
7. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
[TBL] [Abstract][Full Text] [Related]
8. NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function.
You WK; Yotsumoto F; Sakimura K; Adams RH; Stallcup WB
Angiogenesis; 2014 Jan; 17(1):61-76. PubMed ID: 23925489
[TBL] [Abstract][Full Text] [Related]
9. Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy.
Hall AP
Toxicol Pathol; 2006; 34(6):763-75. PubMed ID: 17162534
[No Abstract] [Full Text] [Related]
10. Establishment of a 3D model of tumor-driven angiogenesis to study the effects of anti-angiogenic drugs on pericyte recruitment.
Qiu Y; Wang N; Guo T; Liu S; Tang X; Zhong Z; Chen Q; Wu H; Li X; Wang J; Zhang S; Ou Y; Wang B; Ma K; Gu W; Cao J; Chen H; Duan Y
Biomater Sci; 2021 Sep; 9(18):6064-6085. PubMed ID: 34136892
[TBL] [Abstract][Full Text] [Related]
11. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis.
Guan YY; Luan X; Xu JR; Liu YR; Lu Q; Wang C; Liu HJ; Gao YG; Chen HZ; Fang C
Biomaterials; 2014 Mar; 35(9):3060-70. PubMed ID: 24393268
[TBL] [Abstract][Full Text] [Related]
12. Pericytes derived from adipose-derived stem cells protect against retinal vasculopathy.
Mendel TA; Clabough EB; Kao DS; Demidova-Rice TN; Durham JT; Zotter BC; Seaman SA; Cronk SM; Rakoczy EP; Katz AJ; Herman IM; Peirce SM; Yates PA
PLoS One; 2013; 8(5):e65691. PubMed ID: 23741506
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of tumor neovascularization.
Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ishikura H
Vasc Health Risk Manag; 2005; 1(4):277-90. PubMed ID: 17315600
[TBL] [Abstract][Full Text] [Related]
14. Tumor Microenvironment-Associated Pericyte Populations May Impact Therapeutic Response in Thyroid Cancer.
Iesato A; Nucera C
Adv Exp Med Biol; 2021; 1329():253-269. PubMed ID: 34664244
[TBL] [Abstract][Full Text] [Related]
15. Role of Moesin Phosphorylation in Retinal Pericyte Migration and Detachment Induced by Advanced Glycation Endproducts.
Zhang SS; Hu JQ; Liu XH; Chen LX; Chen H; Guo XH; Huang QB
Front Endocrinol (Lausanne); 2020; 11():603450. PubMed ID: 33312163
[TBL] [Abstract][Full Text] [Related]
16. Olfactomedin-like 3 promotes PDGF-dependent pericyte proliferation and migration during embryonic blood vessel formation.
Imhof BA; Ballet R; Hammel P; Jemelin S; Garrido-Urbani S; Ikeya M; Matthes T; Miljkovic-Licina M
FASEB J; 2020 Nov; 34(11):15559-15576. PubMed ID: 32997357
[TBL] [Abstract][Full Text] [Related]
17. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
Iivanainen E; Lauttia S; Zhang N; Tvorogov D; Kulmala J; Grenman R; Salven P; Elenius K
Microvasc Res; 2009 Dec; 78(3):278-85. PubMed ID: 19596357
[TBL] [Abstract][Full Text] [Related]
18. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Mancuso MR; Davis R; Norberg SM; O'Brien S; Sennino B; Nakahara T; Yao VJ; Inai T; Brooks P; Freimark B; Shalinsky DR; Hu-Lowe DD; McDonald DM
J Clin Invest; 2006 Oct; 116(10):2610-21. PubMed ID: 17016557
[TBL] [Abstract][Full Text] [Related]
19. Connection of pericyte-angiopoietin-Tie-2 system in diabetic retinopathy: friend or foe?
Cai J; Ruan Q; Chen ZJ; Han S
Future Med Chem; 2012 Nov; 4(17):2163-76. PubMed ID: 23190105
[TBL] [Abstract][Full Text] [Related]
20. PDGFR-β inhibitor slows tumor growth but increases metastasis in combined radiotherapy and Endostar therapy.
Yin L; He J; Xue J; Na F; Tong R; Wang J; Gao H; Tang F; Mo X; Deng L; Lu Y
Biomed Pharmacother; 2018 Mar; 99():615-621. PubMed ID: 29653486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
